{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:01:03Z","timestamp":1777982463494,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFC3404000"],"award-info":[{"award-number":["2023YFC3404000"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC3503400"],"award-info":[{"award-number":["2023YFC3503400"]}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82371781"],"award-info":[{"award-number":["82371781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02218-5","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:47:32Z","timestamp":1776455252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting angiopoietin-like protein 3 and interleukin-1\u03b2 alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db\/db mice"],"prefix":"10.1007","volume":"75","author":[{"given":"Shuwen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonglian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuojin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyang","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2218_CR1","doi-asserted-by":"publisher","first-page":"175219","DOI":"10.1016\/j.ejphar.2022.175219","volume":"931","author":"M Yang","year":"2022","unstructured":"Yang M, Luo S, Yang J, Chen W, He L, Liu D, et al. Crosstalk between the liver and kidney in diabetic nephropathy. Eur J Pharmacol. 2022;931:175219.","journal-title":"Eur J Pharmacol"},{"key":"2218_CR2","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/s41467-022-31476-0","volume":"13","author":"H Chen","year":"2022","unstructured":"Chen H, Liu C, Wang Q, et al. Renal UTX-PHGDH-serine axis regulates metabolic disorders in the kidney and liver. Nat Commun. 2022;13:3835.","journal-title":"Nat Commun"},{"key":"2218_CR3","doi-asserted-by":"crossref","unstructured":"Zhang Y, Sun C, Wang Y, et al. Targeting gut-liver-kidney axis: microbiota-derived metabolites and therapeutic implications.\u00a0Cell Commun Signal 2026","DOI":"10.1186\/s12964-025-02625-x"},{"key":"2218_CR4","doi-asserted-by":"publisher","first-page":"156081","DOI":"10.1016\/j.metabol.2024.156081","volume":"163","author":"ZA Kipp","year":"2025","unstructured":"Kipp ZA, Badmus OO, Stec DE, Hall B, Hinds TD Jr. Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: a biomarker for insulin resistance in the cardiovascular-kidney-metabolic (CKM) syndrome. Metab. 2025;163:156081.","journal-title":"Metab"},{"key":"2218_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-021-05585-2","volume":"65","author":"MK Ali","year":"2022","unstructured":"Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65:3\u201313.","journal-title":"Diabetologia"},{"key":"2218_CR6","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.3390\/ijms25147728","volume":"25","author":"CM Alfieri","year":"2024","unstructured":"Alfieri CM, Molinari P, Cinque F, Vettoretti S, Cespiati A, Bignamini D, et al. What not to overlook in the management of patients with type 2 diabetes mellitus: the nephrological and hepatological perspectives. Int J Mol Sci. 2024;25:7728.","journal-title":"Int J Mol Sci"},{"key":"2218_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156\u201362.","journal-title":"Gut"},{"key":"2218_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41467-023-35944-z","volume":"14","author":"TS Huang","year":"2023","unstructured":"Huang TS, Wu T, Wu YD, Li XH, Tan J, Shen CH, et al. Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. Nat Commun. 2023;14:390.","journal-title":"Nat Commun"},{"key":"2218_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","volume":"960","author":"D Yazici","year":"2017","unstructured":"Yazici D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017;960:277\u2013304.","journal-title":"Adv Exp Med Biol"},{"key":"2218_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13:731\u20139.","journal-title":"Nat Rev Endocrinol"},{"key":"2218_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOL.0b013e3283630cf0","volume":"24","author":"M Arca","year":"2013","unstructured":"Arca M, Minicocci I, Maranghi M. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. Curr Opin Lipidol. 2013;24:313\u201320.","journal-title":"Curr Opin Lipidol"},{"key":"2218_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/pr.2015.38","volume":"77","author":"J Liu","year":"2015","unstructured":"Liu J, Gao X, Zhai Y, Shen Q, Sun L, Feng C, et al. A novel role of angiopoietin-like-3 associated with podocyte injury. Pediatr Res. 2015;77:732\u20139.","journal-title":"Pediatr Res"},{"key":"2218_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.bbrc.2004.03.151","volume":"317","author":"K Inukai","year":"2004","unstructured":"Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317:1075\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2218_CR14","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(02)09315-7","volume":"359","author":"RP Naoumova","year":"2002","unstructured":"Naoumova RP, Betteridge DJ. A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome? Lancet. 2002;359:2215\u20136.","journal-title":"Lancet"},{"key":"2218_CR15","doi-asserted-by":"publisher","first-page":"118189","DOI":"10.1016\/j.biopha.2025.118189","volume":"188","author":"SS Tamehri Zadeh","year":"2025","unstructured":"Tamehri Zadeh SS, Toth PP, Shapiro MD, Surma S, Banach M. ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives. Biomed Pharmacother. 2025;188:118189.","journal-title":"Biomed Pharmacother"},{"key":"2218_CR16","doi-asserted-by":"publisher","first-page":"1434145","DOI":"10.3389\/fendo.2024.1434145","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ou G, Peng L, Pan J, Zhang S, Shi J. Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease. Front Endocrinol (Lausanne). 2025;15:1434145.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2218_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41419-023-06124-0","volume":"14","author":"B Ji","year":"2023","unstructured":"Ji B, Liu J, Yin Y, Xu H, Shen Q, Yu J. Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis. Cell Death Dis. 2023;14:601.","journal-title":"Cell Death Dis"},{"key":"2218_CR18","doi-asserted-by":"publisher","first-page":"109715","DOI":"10.1016\/j.intimp.2023.109715","volume":"115","author":"Y Ma","year":"2023","unstructured":"Ma Y, Xie D, Liu J, Han X, Xu H, Chen Y. Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice. Int Immunopharmacol. 2023;115:109715.","journal-title":"Int Immunopharmacol"},{"key":"2218_CR19","doi-asserted-by":"publisher","first-page":"1011442","DOI":"10.3389\/fimmu.2022.1011442","volume":"13","author":"Q Ma","year":"2022","unstructured":"Ma Q, Hu X, Liu F, Cao Z, Han L, Zhou K, et al. A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice. Front Immunol. 2022;13:1011442.","journal-title":"Front Immunol"},{"key":"2218_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12951-022-01456-z","volume":"20","author":"X Hu","year":"2022","unstructured":"Hu X, Fan J, Ma Q, Han L, Cao Z, Xu C, et al. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J Nanobiotechnology. 2022;20:237.","journal-title":"J Nanobiotechnology"},{"key":"2218_CR21","doi-asserted-by":"publisher","first-page":"100446","DOI":"10.1016\/j.xcrm.2021.100446","volume":"2","author":"H Fukami","year":"2021","unstructured":"Fukami H, Morinaga J, Nakagami H, Hayashi H, Okadome Y, Matsunaga E, et al. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep Med. 2021;2:100446.","journal-title":"Cell Rep Med"},{"key":"2218_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2022.09.027","volume":"164","author":"H Li","year":"2023","unstructured":"Li H, Zheng J, Xu Q, Yang Y, Zhou J, Guo X, et al. Hepatocyte adenosine kinase promotes excessive fat deposition and liver inflammation. Gastroenterol. 2023;164:134\u201346.","journal-title":"Gastroenterol"},{"key":"2218_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16:206\u201322.","journal-title":"Nat Rev Nephrol"},{"key":"2218_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","volume":"69","author":"L Zhao","year":"2018","unstructured":"Zhao L, Zhang C, Luo X, Wang P, Zhou W, Zhong S, et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J Hepatol. 2018;69:705\u201317.","journal-title":"J Hepatol"},{"key":"2218_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41419-021-03813-6","volume":"12","author":"Y Hou","year":"2021","unstructured":"Hou Y, Wang Q, Han B, Chen Y, Qiao X, Wang L. CD36 promotes NLRP3 inflammasome activation via the mtROS pathway in renal tubular epithelial cells of diabetic kidneys. Cell Death Dis. 2021;12:523.","journal-title":"Cell Death Dis"},{"key":"2218_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12933-025-02706-8","volume":"24","author":"PG Simeone","year":"2025","unstructured":"Simeone PG, Costantino S, Liani R, Tripaldi R, Di Castelnuovo A, Tartaro A, et al. Interleukin-1beta in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes. Cardiovasc Diabetol. 2025;24:247.","journal-title":"Cardiovasc Diabetol"},{"key":"2218_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ki.2015.125","volume":"88","author":"G Balasubramaniam","year":"2015","unstructured":"Balasubramaniam G, Almond M, Dasgupta B. Improved renal function in diabetic patients with acute gout treated with anakinra. Kidney Int. 2015;88:195\u20136.","journal-title":"Kidney Int"},{"key":"2218_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s42003-023-05091-8","volume":"6","author":"JM Cho","year":"2023","unstructured":"Cho JM, Koh JH, Kim SG, Lee S, Kim Y, Cho S, et al. Mendelian randomization uncovers a protective effect of interleukin-1 receptor antagonist on kidney function. Commun Biol. 2023;6:722.","journal-title":"Commun Biol"},{"key":"2218_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179\u201388.","journal-title":"Nat Med"},{"key":"2218_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","volume":"68","author":"DT Meier","year":"2025","unstructured":"Meier DT, de Paula SJ, Donath MY. Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity. Diabetologia. 2025;68:3\u201316.","journal-title":"Diabetologia"},{"key":"2218_CR31","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1038\/s41467-022-32509-4","volume":"13","author":"DT Meier","year":"2022","unstructured":"Meier DT, Rachid L, Wiedemann SJ, et al. Prohormone convertase 1\/3 deficiency causes obesity due to impaired proinsulin processing. Nat Commun. 2022;13:4761.","journal-title":"Nat Commun"},{"key":"2218_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cmet.2022.06.001","volume":"34","author":"SJ Wiedemann","year":"2022","unstructured":"Wiedemann SJ, Trimigliozzi K, Dror E, et al. The cephalic phase of insulin release is modulated by IL-1\u03b2. Cell Metab. 2022;34:991-1003.e6.","journal-title":"Cell Metab"},{"key":"2218_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4161\/mabs.3.1.13989","volume":"3","author":"AM Owyang","year":"2011","unstructured":"Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs. 2011;3:49\u201360.","journal-title":"MAbs"},{"key":"2218_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41420-024-02167-0","volume":"10","author":"W Xue","year":"2024","unstructured":"Xue W, Xu C, Zhang K, Cui L, Huang X, Nan Y, et al. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. Cell Death Discov. 2024;10:393.","journal-title":"Cell Death Discov"},{"key":"2218_CR35","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","volume":"21","author":"C Xu","year":"2023","unstructured":"Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, et al. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnol. 2023;21:410.","journal-title":"J Nanobiotechnol"},{"key":"2218_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/er.2003-0026","volume":"25","author":"C Bouche","year":"2004","unstructured":"Bouche C, Serdy S, Kahn CR, Goldfine AB. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev. 2004;25:807\u201330.","journal-title":"Endocr Rev"},{"key":"2218_CR37","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1021\/acs.jafc.1c02476","volume":"69","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Yang H, Deng J, Fan D. Ginsenoside Rg5 improves insulin resistance and mitochondrial biogenesis of liver via regulation of the Sirt1\/PGC-1alpha signaling pathway in db\/db mice. J Agric Food Chem. 2021;69:8428\u201339.","journal-title":"J Agric Food Chem"},{"key":"2218_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.phrs.2017.12.026","volume":"130","author":"J Yan","year":"2018","unstructured":"Yan J, Wang C, Jin Y, Meng Q, Liu Q, Liu Z, et al. Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK\/NOX4\/PI3K\/AKT pathway. Pharmacol Res. 2018;130:466\u201380.","journal-title":"Pharmacol Res"},{"key":"2218_CR39","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1021\/acsnano.7b07643","volume":"12","author":"Y Sun","year":"2018","unstructured":"Sun Y, Shi H, Yin S, Ji C, Zhang X, Zhang B, et al. Human Mesenchymal Stem Cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction. ACS Nano. 2018;12:7613\u201328.","journal-title":"ACS Nano"},{"key":"2218_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41467-020-20500-w","volume":"12","author":"A Kumar","year":"2021","unstructured":"Kumar A, Sundaram K, Mu J, Dryden GW, Sriwastva MK, Lei C, et al. High-fat diet-induced upregulation of exosomal phosphatidylcholine contributes to insulin resistance. Nat Commun. 2021;12:213.","journal-title":"Nat Commun"},{"key":"2218_CR41","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","volume":"175","author":"A Koh","year":"2018","unstructured":"Koh A, Molinaro A, Stahlman M, Khan MT, Schmidt C, Manneras-Holm L, et al. Microbially produced Imidazole Propionate impairs insulin signaling through mTORC1. Cell. 2018;175:947-61 e17.","journal-title":"Cell"},{"key":"2218_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-024-02173-7","volume":"23","author":"XZ Hou","year":"2024","unstructured":"Hou XZ, Lv YF, Li YS, Wu Q, Lv QY, Yang YT, et al. Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. Cardiovasc Diabetol. 2024;23:86.","journal-title":"Cardiovasc Diabetol"},{"key":"2218_CR43","first-page":"1245","volume":"10","author":"GE Chung","year":"2022","unstructured":"Chung GE, Han K, Lee KN, Cho EJ, Bae JH, Yang SY, et al. Combined effects of chronic kidney disease and nonalcoholic fatty liver disease on the risk of cardiovascular disease in patients with diabetes. Biomed. 2022;10:1245.","journal-title":"Biomed"},{"key":"2218_CR44","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.7150\/ijbs.100394","volume":"20","author":"J Rong","year":"2024","unstructured":"Rong J, Zhang Z, Peng X, Li P, Zhao T, Zhong Y. Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome. Int J Biol Sci. 2024;20:4783\u201398.","journal-title":"Int J Biol Sci"},{"key":"2218_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.apsb.2020.07.002","volume":"11","author":"Y Shen","year":"2021","unstructured":"Shen Y, Chen W, Han L, Bian Q, Fan J, Cao Z, et al. VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses. Acta Pharm Sin B. 2021;11:127\u201342.","journal-title":"Acta Pharm Sin B"},{"issue":"887\u2013905","key":"2218_CR46","first-page":"e11","volume":"35","author":"N Wieder","year":"2023","unstructured":"Wieder N, Fried JC, Kim C, Sidhom EH, Brown MR, Marshall JL, et al. FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. Cell Metab. 2023;35(887\u2013905):e11.","journal-title":"Cell Metab"},{"key":"2218_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71:1012\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.031.","journal-title":"J Hepatol"},{"key":"2218_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280\u201395.","journal-title":"J Hepatol"},{"key":"2218_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37\u201346.","journal-title":"Nat Med"},{"key":"2218_CR50","doi-asserted-by":"publisher","first-page":"e23399","DOI":"10.1096\/fj.202301564RR","volume":"38","author":"P Zhang","year":"2024","unstructured":"Zhang P, Wang K, Hu T, Xu M, You X, Chen M, et al. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice. FASEB J. 2024;38:e23399.","journal-title":"FASEB J"},{"key":"2218_CR51","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1016\/j.molcel.2022.09.018","volume":"82","author":"T Hou","year":"2022","unstructured":"Hou T, Tian Y, Cao Z, et al. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. Mol Cell. 2022;82:4099-4115.e9.","journal-title":"Mol Cell"},{"key":"2218_CR52","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/antiox12091715","volume":"12","author":"K Su","year":"2023","unstructured":"Su K, Zhao SL, Yang WX, Lo CS, Chenier I, Liao MC, et al. NRF2 deficiency attenuates diabetic kidney disease in Db\/Db mice via down-regulation of angiotensinogen, SGLT2, CD36, and FABP4 expression and lipid accumulation in renal proximal tubular cells. Antioxid (Basel). 2023;12:1715.","journal-title":"Antioxid (Basel)"},{"key":"2218_CR53","doi-asserted-by":"publisher","first-page":"104778","DOI":"10.1016\/j.phrs.2020.104778","volume":"156","author":"K Su","year":"2020","unstructured":"Su K, Yi B, Yao BQ, Xia T, Yang YF, Zhang ZH, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis. Pharmacol Res. 2020;156:104778.","journal-title":"Pharmacol Res"},{"key":"2218_CR54","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/febs.14038","volume":"284","author":"W Chen","year":"2017","unstructured":"Chen W, Jiang Y, Han J, Hu J, He T, Yan T, et al. Atgl deficiency induces podocyte apoptosis and leads to glomerular filtration barrier damage. FEBS J. 2017;284:1070\u201381.","journal-title":"FEBS J"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02218-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:02:16Z","timestamp":1776459736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02218-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02218-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7930376\/v1","asserted-by":"object"}]},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"94"}}